ν˜„λŒ€ADM 둜고

ν˜„λŒ€ADM (187660) μ£Όκ°€ 및 μ’…λͺ© 정보

ν˜„λŒ€ADM μ‹€μ‹œκ°„ μ£Όκ°€

ν˜„λŒ€ADM ν˜„μž¬κ°€ 상세 정보
ν•­λͺ© κ°’
ν˜„μž¬κ°€ 3,005 원
λ³€λ™λŸ‰ β–² 5.00 원
변동λ₯  0.17%
κ±°λž˜λŸ‰ 33,896,904
κ±°λž˜λŒ€κΈˆ 106,282,724,469 원

ν˜„λŒ€ADM 일별 μ£Όκ°€

ν˜„λŒ€ADM의 κ³Όκ±° 일별 μ£Όκ°€
λ‚ μ§œ μ‹œκ°€ κ³ κ°€ μ €κ°€ μ’…κ°€ κ±°λž˜λŸ‰ κ±°λž˜λŒ€κΈˆ
8/17/2025 1,672 1,928 1,626 1,835 16,070,621 29,548,406,066
8/18/2025 1,820 2,310 1,797 2,140 37,766,219 80,405,888,027
8/19/2025 2,140 2,285 1,947 1,950 11,383,129 24,103,177,089
8/20/2025 1,963 2,090 1,889 1,905 4,619,912 9,113,932,881
8/21/2025 1,921 1,980 1,845 1,870 2,344,021 4,473,227,192
8/24/2025 1,873 2,040 1,833 1,915 6,195,881 12,172,779,650
8/25/2025 1,920 2,275 1,909 2,165 17,436,787 37,984,209,173
8/26/2025 2,215 2,460 2,145 2,310 12,880,687 30,210,937,319
8/27/2025 2,325 3,000 2,240 3,000 34,980,949 96,352,211,195
8/28/2025 3,280 3,385 2,880 3,005 33,896,904 106,282,724,469

κ΄€λ ¨ ν…Œλ§ˆ

ν˜„λŒ€ADM νšŒμ‚¬ 정보

μ‹œμž₯ μ‹œκ°€μ΄μ•‘ κΈ°μ—…μˆœμœ„ μ£Όμ‹μˆ˜ 외ꡭ인 비쀑 μ‚°μ—…κ΅° μ„ΈλΆ€ μ‚°μ—…κ΅° 52μ£Ό 졜고 52μ£Ό μ΅œμ €
kosdaq 1,452μ–΅ 572μœ„ 48,347,668 1.55% ν—¬μŠ€μΌ€μ–΄ 생λͺ…κ³Όν•™/곡학 3,375 1,118

ν˜„λŒ€ADM κΈ°μ—… κ°œμš”

μ—μ΄λ””μ— μ½”λ¦¬μ•„λŠ” 2003λ…„ 10μ›” μ„€λ¦½λœ κΈ°μ—…μœΌλ‘œ μž„μƒμ‹œν—˜ μˆ˜νƒκΈ°κ΄€μœΌλ‘œ μ œμ•½νšŒμ‚¬, λ°”μ΄μ˜€λ²€μ²˜ 등에 μž„μƒμ‹œν—˜κ³Ό κ΄€λ ¨ν•œ μ „ μ˜μ—­μ— 걸친 μ„œλΉ„μŠ€ 사업을 μ˜μœ„ν•˜κ³  μžˆλ‹€. μ£Όμš” 쒅속기업은 μ—μ΄λ””μ— λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€(μ£Ό)κ°€ μžˆλ‹€. μ£Όμš” λ§€μΆœμ€ μš©μ—­ λΆ€λ¬Έμ—μ„œ λ°œμƒν•˜κ³  μžˆλ‹€. μ‹ μ•½μ˜ μ‹œνŒμ„ μœ„ν•΄μ„œλŠ” μž‘κ²ŒλŠ” 5λ…„μ—μ„œ 평균 10λ…„ λ™μ•ˆ 단계별 μž„μƒμ‹œν—˜(1상, 2상, 3상)을 μˆ˜ν–‰ν•΄μ•Ό ν•˜λ©°, λ‹Ήμ‚¬λŠ” μ΄λŸ¬ν•œ 역할을 μˆ˜ν–‰ν•˜κΈ° μœ„ν•΄ κ³ κ°μ‚¬λ‘œλΆ€ν„° μž„μƒμ‹œν—˜μ— κ΄€ν•œ 전체 λ˜λŠ” 일뢀 업무λ₯Ό μœ„νƒ λ°›μ•„ μˆ˜ν–‰ν•˜κ³  μžˆλ‹€.

μ΅œμ‹  ν˜„λŒ€ADM κ΄€λ ¨ λ‰΄μŠ€

ν˜„λŒ€ADM이 λ‹·μƒˆμ§Έ μƒμŠΉ 흐름을 이어가고 μžˆλ‹€. ν˜„λŒ€λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€μ™€ 곡동 개발 쀑인 μ‹ μ•½ 후보 νŽ˜λ‹ˆνŠΈλ¦¬μ›€(λ‹ˆν΄λ‘œμ‚¬λ§ˆμ΄λ“œ 기반 λ‚˜λ…Έν•˜μ΄λΈŒλ¦¬λ“œ)의 연ꡬ 초둝이 세계 졜고 κΆŒμœ„ μ•”ν•™νšŒμΈ 'AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2025'에 곡식 채택돼 ν¬μŠ€ν„° λ°œν‘œλ‘œ μ§„ν–‰ν•œλ‹€λŠ” μ†Œμ‹μ΄ 주가에 영ν–₯을 μ£ΌλŠ” κ²ƒμœΌλ‘œ 보인닀. ν˜„λŒ€ADM은 29일 μ˜€μ „ 9μ‹œ24λΆ„ κΈ°μ€€ μ „κ±°λž˜μΌ λŒ€λΉ„ 125원(4.17%) 였λ₯Έ 3125원에 κ±°λž˜λλ‹€

28일 μœ κ°€μ¦κΆŒ μ‹œμž₯μ—μ„œ μƒν•œκ°€λ₯Ό κΈ°λ‘ν•œ μ’…λͺ©μ€ μ—†μ—ˆλ‹€. ν•˜ν•œκ°€λ₯Ό κΈ°λ‘ν•œ μ’…λͺ©λ„ μ—†μ—ˆλ‹€. 같은 λ‚  μ½”μŠ€λ‹₯ μ‹œμž₯μ—μ„œλŠ” △동일...

ν˜„λŒ€ADMλ°”μ΄μ˜€κ°€ κ°•μ„Έλ‹€. λͺ¨νšŒμ‚¬ ν˜„λŒ€λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€μ™€ 곡동 개발 쀑인 μ‹ μ•½ 후보 νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium, λ‹ˆν΄λ‘œμ‚¬λ§ˆμ΄λ“œ 기반 λ‚˜λ…Έν•˜μ΄λΈŒλ¦¬λ“œ)의 연ꡬ 초둝이 세계 졜고 κΆŒμœ„ μ•”ν•™νšŒμΈ 'AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2025'에 곡식 μ±„νƒλλ‹€λŠ” μ†Œμ‹μ΄ 주가에 영ν–₯을 μ£ΌλŠ” κ²ƒμœΌλ‘œ 보인닀. AACR-NCI-EORTC ν•™νšŒλŠ” λ―Έκ΅­ μ•”μ—°κ΅¬ν•™νšŒ(AACR), λ―Έκ΅­ κ΅­λ¦½μ•”μ—°κ΅¬μ†Œ(NCI), 유럽 μ•”μ—°κ΅¬μΉ˜λ£ŒκΈ°κ΅¬(EORTC)κ°€ 곡동

[νŒŒμ΄λ‚Έμ…œλ‰΄μŠ€]Β ν˜„λŒ€ADM은 λͺ¨νšŒμ‚¬ ν˜„λŒ€λ°”μ΄μ˜€μ™€ 곡동 개발 쀑인 μ‹ μ•½ 후보 'νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium)'의 연ꡬ 초둝이 세계 졜고 κΆŒμœ„ μ•”ν•™νšŒμΈ 'AACR-NCI-EORTC 2025'에 곡식 채택돼 ν¬μŠ€ν„° λ°œν‘œλ‘œ μ§„ν–‰λœλ‹€κ³  28일 λ°ν˜”λ‹€. 이번 채택은 ν•œκ΅­μ΄ μ œκΈ°ν•œ μƒˆλ‘œμš΄ ν•­μ•”μΉ˜λ£Œ νŒ¨λŸ¬λ‹€μž„μΈ 'κ°€μ§œλ‚΄μ„±'(pseudo-resistance) κ°œλ…μ΄ 세계 졜고 κΆŒμœ„ μ•”ν•™νšŒμ—μ„œ κ³΅μΈλμŒμ„ λœ»ν•œλ‹€. 이둜써 μ•”μΉ˜λ£Œμ˜ 근본적 μ „ν™˜μ„ μ•Œλ¦¬λŠ” 역사적 μ„±κ³ΌλΌλŠ” 평가가 λ‚˜μ˜¨λ‹€. μ±„νƒλœ 초둝의 제λͺ©μ€ 'Disrupting the oncobiosphere: CAF-targeting therapy with Penetrium reverses pseudo-resistance in tumors'둜, μ§€λ‚œ 80λ…„ κ°„ ν•­μ•” μ‹€νŒ¨μ˜ μ›μΈμœΌλ‘œ μ—¬κ²¨μ˜¨ 'μœ μ „μž λ‚΄μ„±' 가섀을 λ’€μ§‘κ³ , μ’…μ–‘ λ―Έμ„Έν™˜κ²½μ˜ ꡬ쑰적 μž₯λ²½(μ•”μ—°κ΄€ μ„¬μœ μ•„μ„Έν¬, μ΄ν•˜ CAF)κ³Ό CAFκ°€ λ§Œλ“  병리적 μ„Έν¬μ™ΈκΈ°μ§ˆ(Extracellular Matrix, ECM)이 ν•­μ•” μ‹€νŒ¨μ˜ 본질적 μ›μΈμž„μ„ 세계

ν˜„λŒ€ADM 맀좜 정보

λ‚ μ§œ λ§€μΆœμ•‘ λ§€μΆœμ•‘ μ¦κ°€μœ¨ μ˜μ—…μ΄μ΅ μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨ 순이읡 순이읡 μ¦κ°€μœ¨
2024.4Q 9,744,986,676 -29.33% -15,932,446,161 -359.86% -20,260,475,756 -502.40%
2023.4Q 13,790,195,699 -7.34% -3,464,613,885 -359.05% -3,363,294,388 -5611.85%
2022.4Q 14,882,556,000 6.47% -754,740,500 -136.10% -58,882,744 -103.41%
2021.4Q 13,977,772,000 - 2,090,550,500 - 1,726,994,300 -

μˆœλ§€μˆ˜λŸ‰

개인: 127,659

κΈ°κ΄€: -25

외인: -144,995

λˆ„μ  μˆœλ§€μˆ˜λŸ‰

개인: 2,712,371

κΈ°κ΄€: -2,358,489

외인: -340,493

순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-08-29 127,659 -25 -144,995
2025-08-28 202,484 25 -209,774
2025-08-27 -223,819 - 217,438
2025-08-26 -491,362 - 506,645
2025-08-25 98,451 -140 -100,786
2025-08-22 -54,116 - 44,478
2025-08-21 512,075 140 -511,782
2025-08-20 -15,753 - 32,563
2025-08-19 -120,552 - 140,980
2025-08-18 -368,671 - 364,483
2025-08-14 -37,281 - 37,108
2025-08-13 -33,640 - 31,085
2025-08-12 187,940 - -170,399
2025-08-11 42,372 - -43,872
2025-08-08 -27,200 - 27,499
2025-08-07 -9,115 - 8,602
2025-08-06 -38,099 - 67,402
2025-08-05 146,583 - -146,623
2025-08-04 332,457 -378,497 42,670
2025-08-01 51,821 -6,871 -46,950
2025-07-31 -30,876 - 30,867

λˆ„μ  순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-08-29 251,358 -385,368 176,639
2025-08-28 123,699 -385,343 321,634
2025-08-27 -78,785 -385,368 531,408
2025-08-26 145,034 -385,368 313,970
2025-08-25 636,396 -385,368 -192,675
2025-08-22 537,945 -385,228 -91,889
2025-08-21 592,061 -385,228 -136,367
2025-08-20 79,986 -385,368 375,415
2025-08-19 95,739 -385,368 342,852
2025-08-18 216,291 -385,368 201,872
2025-08-14 584,962 -385,368 -162,611
2025-08-13 622,243 -385,368 -199,719
2025-08-12 655,883 -385,368 -230,804
2025-08-11 467,943 -385,368 -60,405
2025-08-08 425,571 -385,368 -16,533
2025-08-07 452,771 -385,368 -44,032
2025-08-06 461,886 -385,368 -52,634
2025-08-05 499,985 -385,368 -120,036
2025-08-04 353,402 -385,368 26,587
2025-08-01 20,945 -6,871 -16,083
2025-07-31 -30,876 - 30,867

ν˜„λŒ€ADM μžμ‚° λΉ„μœ¨

μžμ‚°μ΄κ³„ λΆ€μ±„λΉ„μœ¨ μžλ³ΈλΉ„μœ¨
26,159,138,672 67.70% 32.30%

ν˜„λŒ€ADM 맀좜 ꡬ성

ꡬ성 μš”μ†Œ λΉ„μœ¨
Clinical trial [μš©μ—­] 64.9%
LPS [μš©μ—­] 32.9%
μž„λŒ€ 1.9%
μƒν’ˆ [μž¬ν™”μ˜] 0.3%

ν˜„λŒ€ADM 곡맀도 ν˜„ν™©

졜근 곡맀도 κ±°λž˜λŸ‰: 4,190 (0.01%)

졜근 곡맀도 μž”κ³ : 195,791 (0.4%)

곡맀도 κ±°λž˜λŸ‰

λ‚ μ§œ μ’…κ°€ κ³΅λ§€λ„λŸ‰ 곡맀도비쀑
2025-08-29 3,005 4,190 0.01%
2025-08-28 3,000 26,819 0.08%
2025-08-27 2,310 0 0.00%
2025-08-26 2,165 3,969 0.02%
2025-08-25 1,915 4,305 0.07%
2025-08-22 1,870 2,038 0.09%
2025-08-21 1,905 18,696 0.40%
2025-08-20 1,950 3,919 0.03%
2025-08-19 2,140 119,982 0.32%
2025-08-18 1,835 6,970 0.04%
2025-08-14 1,672 16,955 0.54%
2025-08-13 1,728 18,364 0.11%
2025-08-12 1,640 18,096 0.09%
2025-08-11 1,443 20,842 2.41%
2025-08-08 1,435 12,481 1.98%
2025-08-07 1,388 11,487 2.42%
2025-08-06 1,403 4,952 0.72%
2025-08-05 1,419 5,695 0.67%
2025-08-04 1,440 15,880 0.36%
2025-08-01 1,436 26,034 2.74%
2025-07-31 1,486 2,926 0.44%

곡맀도 μž”κ³ 

λ‚ μ§œ μ’…κ°€ 곡맀도 μž”κ³  곡맀도 비쀑
2025-08-27 2,310 195,791 0.40%
2025-08-26 2,165 234,121 0.48%
2025-08-25 1,915 334,346 0.69%
2025-08-22 1,870 297,980 0.62%
2025-08-21 1,905 327,464 0.68%
2025-08-20 1,950 215,182 0.45%
2025-08-19 2,140 241,784 0.50%
2025-08-18 1,835 207,330 0.43%
2025-08-14 1,672 208,306 0.43%
2025-08-13 1,728 339,805 0.70%
2025-08-12 1,640 348,952 0.72%
2025-08-11 1,443 312,692 0.65%
2025-08-08 1,435 304,470 0.63%
2025-08-07 1,388 348,991 0.72%
2025-08-06 1,403 376,052 0.78%
2025-08-05 1,419 373,338 0.77%
2025-08-04 1,440 319,587 0.66%
2025-08-01 1,436 330,639 0.68%
2025-07-31 1,486 295,374 0.61%
2025-07-30 1,523 273,424 0.57%
2025-07-29 1,511 194,493 0.40%

ν˜„λŒ€ADM μ—…μ’… λ‚΄ 비ꡐ

생λͺ…κ³Όν•™/곡학 μ—…μ’…(90개) μ—°κ°„ κΈ°μ€€

ν•­λͺ© ν˜„λŒ€ADM μ—…μ’… 평균 μ—…μ’… λ‚΄ μˆœμœ„
μ‹œκ°€μ΄μ•‘ 1,450.43 8,337.69 45μœ„
PER(졜근4λΆ„κΈ°) -18.299 724.29 69μœ„
PBR 16.088 15.5 12μœ„
ROE(졜근4λΆ„κΈ°) -118.306 -33.71 83μœ„
λ°°λ‹Ήμˆ˜μ΅λ₯ (μ΅œκ·Όμ—°λ„) - - -μœ„
μ˜μ—…μ΄μ΅λ₯ (μ΅œκ·Όμ—°λ„) -163.494 -1,735.95 46μœ„
순이읡λ₯ (μ΅œκ·Όμ—°λ„) -207.907 -1,637.93 53μœ„
λΆ€μ±„λΉ„μœ¨(μ΅œκ·Όμ—°λ„) 330.363 77.85 2μœ„
λ§€μΆœμ•‘(μ΅œκ·Όμ—°λ„) 97.45 483.11 39μœ„
μ˜μ—…μ΄μ΅(μ΅œκ·Όμ—°λ„) -159.324 -85.51 64μœ„
λ‹ΉκΈ°μˆœμ΄μ΅(μ΅œκ·Όμ—°λ„) -202.605 -70.67 70μœ„